CBD oil extract reduced anxiety symptoms in most patients over 12 months in a Colombian clinic

After 6 months at median 100 mg CBD daily, 54% still had significant anxiety. After 12 months at median 120 mg, only 37.5% persisted with significant symptoms. Sleep disturbances improved from 46.8% reporting significant daytime sleepiness at baseline to only 12.5% at 12 months. No clinically relevant adverse reactions or deaths occurred during follow-up.

Retrospective observational case series from Zerenia Clinic, Bogota, Colombia (June 2021-December 2022). 24 adults prescribed CBD-enriched oil (100 mg/mL CBD, <1.9 mg/mL THC) for DSM-5 unspecified anxiety disorder. HADS-A, CGI-S/I, HADS-D, and ESS assessed at baseline, 6, and 12 months.

This is one of the few studies tracking CBD treatment for anxiety beyond 6 months, showing continued improvement from 6 to 12 months. The real-world clinical setting adds practical relevance, though the lack of a control group limits conclusions.

The continued improvement between 6 and 12 months suggests CBD may require sustained use for full anxiolytic effects, which has implications for trial design and clinical expectations. The COVID-19 pandemic context adds a naturalistic stress condition.

No control group or randomization. Very small sample (24). Unspecified anxiety disorder is a broad category. Full-spectrum extract with trace THC, not pure CBD. Cannot rule out placebo effects or natural symptom fluctuation. Retrospective design.